SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

VRXI OABI veraxa Biotech announces advancement of novel bispecific antibody drug conjugate program vxa-222 from Joint Discovery collaboratio

VRXI OABI veraxa Biotech announces advancement of novel bispecific antibody drug conjugate program vxa-222 from Joint Discovery collaboration with Omniab

OABI

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.